2020年2月26日 · In the KEYNOTE-522 trial, we evaluated the effect of neoadjuvant treatment on pathological complete response at the time of definitive surgery as well as the effect of both neoadjuvant and ...

2024年9月15日 · KEYNOTE-522 is a phase 3, prospective, randomized, placebo-controlled trial of neoadjuvant and adjuvant pembrolizumab treatment showing significant improvements in overall survival, event-free ...

KEYNOTE-522. • KEYNOTE-522 was the name of the first study that found this regimen to effectively treat breast cancer • KEYNOTE-522 consists of a combination of medications given IV (into the vein) given in 2 parts. Your provider may reverse the sequence in which the 2 parts are given. • Paclitaxel (T axol) • C arboplatin (Paraplatin ...

Health care professionals may view findings from KEYNOTE-522, a clinical trial for patients with high-risk early-stage triple-negative breast cancer (TNBC).

2022年2月9日 · KEYNOTE-522 was a prospective, randomized, placebo-controlled, phase 3 trial of neoadjuvant and adjuvant pembrolizumab treatment in patients with early triple-negative breast cancer.

2022年6月8日 · KEYNOTE-522是一项随机对照的多中心III期临床研究，入组T1c N1-2或T2 N0-2的三阴型乳腺癌患者，按2∶1随机分为试验组与对照组，对照组接受4周期紫杉醇＋卡序贯4周期多柔比星或表柔比星＋环磷酰胺化疗联合安慰剂治疗，试验组接受相同方案的化疗联合帕博利珠单抗 ...

2018年6月1日 · KEYNOTE-522 (NCT03036488) is a phase III study of pembro+chemo vs placebo+chemo as neoadjuvant treatment, followed by pembro vs placebo as adjuvant treatment in pts with TNBC. Methods: Approximately 855 pts with TNBC, defined as combined primary tumor (T) and regional lymph node (N) staging per AJCC (investigator-assessed: T1c N1-2, T2 …

keynote-522研究是一项前瞻性、随机、双盲、多中心的iii期研究，旨在评估帕博利珠单抗联合化疗用于高危早期三阴性乳腺癌（tnbc）患者的 新辅助治疗 和后续帕博利珠单抗单药用于辅助治疗。让我们再来简单回顾下k药在tnbc领域的进阶之路。

keynote-522研究（nct03036488）探索了早期三阴性乳腺癌（tnbc）患者在化疗中加入帕博利珠单抗的获益，初步结果显示帕博利珠单抗对病理完全缓解率（pcr）和无事件生存（efs）的改善具有统计学意义和临床意义。

2024年12月17日 · keynote-522 研究是一项随机、安慰剂对照的iii 期临床试验，旨在探索帕博利珠单抗用于初诊、初治、高风险、早期三阴性乳腺癌（tnbc）（t1c n1–2 或 t2–4 n0–2）患者的新辅助和辅助治疗的相关问题。